Cancer Immunotherapy and the Nectin Family

Literature Cited

1. Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE et al. 2019. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571:265–69
   [Google Scholar]
2. Ardolino M, Zingoni A, Cerboni C, Cecere F, Soriani A et al. 2011. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood 117:4778–86
   [Google Scholar]
3. Barrow AD, Edeling MA, Trifonov V, Luo J, Goyal P et al. 2018. Natural killer cells control tumor growth by sensing a growth factor. Cell 172:534–48.e19
   [Google Scholar]
4. Bevelacqua V, Bevelacqua Y, Candido S, Skarmoutsou E, Amoroso A et al. 2012. Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget 3:882–92
   [Google Scholar]
5. Blake SJ, Stannard K, Liu J, Allen S, Yong MC et al. 2016. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov 6:446–59
   [Google Scholar]
6. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M et al. 2003. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198:557–67
   [Google Scholar]
7. Braun M, Das I, Roman Aguilera A, Sundarrajan A, Corvino D et al. 2020. Tumor CD155 drives resistance to immunotherapy by downregulating the activating receptor CD226 in CD8⁺ T cells. Immunity press
   [Google Scholar]
8. Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S et al. 2018. Perioperative, spatiotemporally coordinated activation of T and NK cells prevents recurrence of pancreatic cancer. Cancer Res 78:475–88
   [Google Scholar]
9. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S et al. 2013. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210:1685–93
   [Google Scholar]
10. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL 2014. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. Immunol. Cell Biol. 92:475–80
    [Google Scholar]
11. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K et al. 2009. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J. Immunol. 183:4921–30
    [Google Scholar]
12. Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E et al. 2009. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol. Immunother. 58:1517–26
    [Google Scholar]
13. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D et al. 2004. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 64:9180–84
    [Google Scholar]
14. Cella M, Presti R, Vermi W, Lavender K, Turnbull E et al. 2010. Loss of DNAM-1 contributes to CD8⁺ T-cell exhaustion in chronic HIV-1 infection. Eur. J. Immunol. 40:949–54
    [Google Scholar]
15. Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT et al. 2014. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15:431–38
    [Google Scholar]
16. Chauvin JM, Ka M, Pagliano O, Menna C, Ding Q et al. 2020. IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma. Clin. Cancer Res. 26:5520–33
    [Google Scholar]
17. Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H et al. 2015. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. J. Clin. Investig. 125:2046–58
    [Google Scholar]
18. Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D et al. 2017. An Immune atlas of clear cell renal cell carcinoma. Cell 169:736–49.e18
    [Google Scholar]
19. Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL et al. 2016. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLOS Pathog 12:e1005349
    [Google Scholar]
20. Chiang EY, de Almeida PE, de Almeida Nagata DE, Bowles KH, Du X et al. 2020. CD96 functions as a co-stimulatory receptor to enhance CD8⁺ T cell activation and effector responses. Eur. J. Immunol. 50:891–902
    [Google Scholar]
21. Chiu DKC, Yuen VWH, Cheu JWS, Wei LL, Ting Vet al 2020. Hepatocellular carcinoma cells upregulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice. Gastroenterology 159:2609–23
    [Google Scholar]
22. Chung W, Eum HH, Lee HO, Lee KM, Lee HB et al. 2017. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat. Commun. 8:15081
    [Google Scholar]
23. Croxford JL, Tang ML, Pan MF, Huang CW, Kamran N et al. 2013. ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood 121:2512–21
    [Google Scholar]
24. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV 2015. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28:285–95
    [Google Scholar]
25. Deuss FA, Gully BS, Rossjohn J, Berry R 2017. Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT). J. Biol. Chem. 292:11413–22
    [Google Scholar]
26. Deuss FA, Watson GM, Fu Z, Rossjohn J, Berry R 2019a. Structural basis for CD96 immune receptor recognition of nectin-like protein-5, CD155. Structure 27:219–28.e3
    [Google Scholar]
27. Deuss FA, Watson GM, Goodall KJ, Leece I, Chatterjee S et al. 2019b. Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1. J. Biol. Chem. 294:12534–46
    [Google Scholar]
28. Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z et al. 2018. Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J. Immunol. 200:3000–7
    [Google Scholar]
29. Dougall WC, Kurtulus S, Smyth MJ, Anderson AC 2017. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol. Rev. 276:112–20
    [Google Scholar]
30. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL et al. 2007. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 67:8444–49
    [Google Scholar]
31. Escalante NK, von Rossum A, Lee M, Choy JC 2011. CD155 on human vascular endothelial cells attenuates the acquisition of effector functions in CD8 T cells. Arterioscler. Thromb. Vasc. Biol. 31:1177–84
    [Google Scholar]
32. Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M 2015. NKG2D and DNAM-1 ligands: molecular targets for NK cell–mediated immunotherapeutic intervention in multiple myeloma. Biomed. Res. Int. 2015:178698
    [Google Scholar]
33. Foks AC, Ran IA, Frodermann V, Bot I, van Santbrink PJ et al. 2013. Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development. PLOS ONE 8:e83134
    [Google Scholar]
34. Fourcade J, Sun Z, Chauvin JM, Ka M, Davar D et al. 2018. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight 3:14e121157
    [Google Scholar]
35. Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JJ et al. 2020. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. J. Clin. Investig. 130:1405–16
    [Google Scholar]
36. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M 2004. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J. Immunol. 172:3994–98
    [Google Scholar]
37. Gao J, Zheng Q, Xin N, Wang W, Zhao C 2017. CD155, an onco-immunologic molecule in human tumors. Cancer Sci 108:1934–38
    [Google Scholar]
38. Gaud G, Roncagalli R, Chaoui K, Bernard I, Familiades J et al. 2018. The costimulatory molecule CD226 signals through VAV1 to amplify TCR signals and promote IL-17 production by CD4⁺ T cells. Sci. Signal. 11:538eear3083
    [Google Scholar]
39. Georgiev H, Ravens I, Papadogianni G, Bernhardt G 2018. Coming of age: CD96 emerges as modulator of immune responses. Front. Immunol. 9:1072
    [Google Scholar]
40. Georgiev H, Ravens I, Shibuya A, Forster R, Bernhardt G 2016. CD155/CD226-interaction impacts on the generation of innate CD8⁺ thymocytes by regulating iNKT-cell differentiation. Eur. J. Immunol. 46:993–1003
    [Google Scholar]
41. Gromeier M, Solecki D, Patel DD, Wimmer E 2000. Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis. Virology 273:248–57
    [Google Scholar]
42. Guillamon CF, Martinez-Sanchez MV, Gimeno L, Campillo JA, Server-Pastor G et al. 2019. Activating KIRs on educated NK cells support downregulation of CD226 and inefficient tumor immunosurveillance. Cancer Immunol. Res. 7:1307–17
    [Google Scholar]
43. Guillerey C, Harjunpaa H, Carrie N, Kassem S, Teo T et al. 2018. TIGIT immune checkpoint blockade restores CD8⁺ T-cell immunity against multiple myeloma. Blood 132:1689–94
    [Google Scholar]
44. Ha D, Tanaka A, Kibayashi T, Tanemura A, Sugiyama D et al. 2019. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. PNAS 116:609–18
    [Google Scholar]
45. Harrison OJ, Vendome J, Brasch J, Jin X, Hong S et al. 2012. Nectin ectodomain structures reveal a canonical adhesive interface. Nat. Struct. Mol. Biol. 19:906–15
    [Google Scholar]
46. Hirota T, Irie K, Okamoto R, Ikeda W, Takai Y 2005. Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf–MEK–ERK–AP-1 pathway. Oncogene 24:2229–35
    [Google Scholar]
47. Holmes VM, Maluquer de Motes C, Richards PT, Roldan J, Bhargava AK et al. 2019. Interaction between nectin-1 and the human natural killer cell receptor CD96. PLOS ONE 14:e0212443
    [Google Scholar]
48. Huang DW, Huang M, Lin XS, Huang Q 2017. CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. OncoTargets Ther 10:3817–25
    [Google Scholar]
49. Huang X, Qu P, Chen Y, Zhou X, Wu Y et al. 2014. Low expression of CD112 is associated with poor overall survival in patients with hepatocellular carcinoma. Hum. Pathol. 45:1944–50
    [Google Scholar]
50. Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D et al. 2018. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology 7:e1466769
    [Google Scholar]
51. Husain B, Ramani SR, Chiang E, Lehoux I, Paduchuri S et al. 2019. A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3/CD276 and PVR/CD155. Mol. Cell Proteom. 18:2310–23
    [Google Scholar]
52. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S et al. 2008. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J. Exp. Med. 205:2959–64
    [Google Scholar]
53. Iguchi-Manaka A, Okumura G, Kojima H, Cho Y, Hirochika R et al. 2016. Increased soluble CD155 in the serum of cancer patients. PLOS ONE 11:e0152982
    [Google Scholar]
54. Ikeda W, Kakunaga S, Itoh S, Shingai T, Takekuni K et al. 2003. Tage4/nectin-like molecule-5 heterophilically trans-interacts with cell adhesion molecule nectin-3 and enhances cell migration. J. Biol. Chem. 278:28167–72
    [Google Scholar]
55. Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S 2016. Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase. J. Investig. Dermatol. 136:255–63
    [Google Scholar]
56. Jin HS, Ko M, Choi DS, Kim JH, Lee DH et al. 2020. CD226^hiCD8⁺ T cells are a prerequisite for anti-TIGIT immunotherapy. Cancer Immunol. Res. 204:1 Suppl.165.10
    [Google Scholar]
57. Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M et al. 2014. The immunoreceptor TIGIT regulates antitumor and antiviral CD8⁺ T cell effector function. Cancer Cell 26:923–37
    [Google Scholar]
58. Joller N, Lozano E, Burkett PR, Patel B, Xiao S et al. 2014. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40:569–81
    [Google Scholar]
59. Kakunaga S, Ikeda W, Shingai T, Fujito T, Yamada A et al. 2004. Enhancement of serum- and platelet-derived growth factor-induced cell proliferation by Necl-5/Tage4/poliovirus receptor/CD155 through the Ras-Raf-MEK-ERK signaling. J. Biol. Chem. 279:36419–25
    [Google Scholar]
60. Kamran N, Takai Y, Miyoshi J, Biswas SK, Wong JS, Gasser S 2013. Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. PLOS ONE 8:e54406
    [Google Scholar]
61. Kearney CJ, Ramsbottom KM, Voskoboinik I, Darcy PK, Oliaro J 2016. Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing. OncoImmunology 5:e1196308
    [Google Scholar]
62. Khan O, Giles JR, McDonald S, Manne S, Ngiow SF et al. 2019. TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. Nature 571:211–18
    [Google Scholar]
63. Kinugasa M, Amano H, Satomi-Kobayashi S, Nakayama K, Miyata M et al. 2012. Necl-5/poliovirus receptor interacts with VEGFR2 and regulates VEGF-induced angiogenesis. Circ. Res. 110:716–26
    [Google Scholar]
64. Koike S, Horie H, Ise I, Okitsu A, Yoshida M et al. 1990. The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J 9:3217–24
    [Google Scholar]
65. Kono T, Imai Y, Yasuda S, Ohmori K, Fukui H et al. 2008. The CD155/poliovirus receptor enhances the proliferation of ras-mutated cells. Int. J. Cancer 122:317–24
    [Google Scholar]
66. Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O, Jonjić S 2019. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol. Immunol. 16:40–52
    [Google Scholar]
67. Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ et al. 2015. TIGIT predominantly regulates the immune response via regulatory T cells. J. Clin. Investig. 125:4053–62
    [Google Scholar]
68. Lange R, Peng X, Wimmer E, Lipp M, Bernhardt G 2001. The poliovirus receptor CD155 mediates cell-to-matrix contacts by specifically binding to vitronectin. Virology 285:218–27
    [Google Scholar]
69. Lepletier A, Lutzky VP, Mittal D, Stannard K, Watkins TS et al. 2019. The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. Immunol. Cell Biol. 97:152–64
    [Google Scholar]
70. Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY et al. 2020. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clin. Cancer Res. 26:143671–81
    [Google Scholar]
71. Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED et al. 2011. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur. J. Immunol. 41:902–15
    [Google Scholar]
72. Li M, Xia P, Du Y, Liu S, Huang G et al. 2014. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling. J. Biol. Chem. 289:17647–57
    [Google Scholar]
73. Li XY, Das I, Lepletier A, Addala V, Bald T et al. 2018. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J. Clin. Investig. 128:2613–25
    [Google Scholar]
74. Liu J, Qian X, Chen Z, Xu X, Gao F et al. 2012. Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226. J. Immunol. 188:5511–20
    [Google Scholar]
75. Liu S, Zhang H, Li M, Hu D, Li C et al. 2013. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ 20:456–64
    [Google Scholar]
76. Liu X, An T, Li D, Fan Z, Xiang P et al. 2019. Structure of the heterophilic interaction between the nectin-like 4 and nectin-like 1 molecules. PNAS 116:2068–77
    [Google Scholar]
77. Lopez M, Aoubala M, Jordier F, Isnardon D, Gomez S, Dubreuil P 1998. The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule. Blood 92:4602–11
    [Google Scholar]
78. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA 2012. The TIGIT/CD226 axis regulates human T cell function. J. Immunol. 188:3869–75
    [Google Scholar]
79. Lucca LE, Axisa PP, Singer ER, Nolan NM, Dominguez-Villar M, Hafler DA 2019. TIGIT signaling restores suppressor function of Th1 Tregs. JCI Insight 4:e124427
    [Google Scholar]
80. Mandai K, Rikitake Y, Mori M, Takai Y 2015. Nectins and nectin-like molecules in development and disease. Curr. Top. Dev. Biol. 112:197–231
    [Google Scholar]
81. Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C et al. 2001. Overexpression of the CD155 gene in human colorectal carcinoma. Gut 49:236–40
    [Google Scholar]
82. Mastaglio S, Wong E, Perera T, Ripley J, Blombery P et al. 2018. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Adv 2:335–46
    [Google Scholar]
83. Mendelsohn CL, Wimmer E, Racaniello VR 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855–65
    [Google Scholar]
84. Miao X, Yang ZL, Xiong L, Zou Q, Yuan Y et al. 2013. Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Int. J. Clin. Exp. Pathol. 6:179–90
    [Google Scholar]
85. Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN et al. 2018. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood 132:1675–88
    [Google Scholar]
86. Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K et al. 2019. CD96 is an immune checkpoint that regulates CD8⁺ T-cell antitumor function. Cancer Immunol. Res. 7:559–71
    [Google Scholar]
87. Molfetta R, Milito ND, Zitti B, Lecce M, Fionda C et al. 2019. The Ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing. Eur. J. Immunol. 49:873–83
    [Google Scholar]
88. Mueller S, Wimmer E. 2003. Recruitment of nectin-3 to cell-cell junctions through trans-heterophilic interaction with CD155, a vitronectin and poliovirus receptor that localizes to α_vβ₃ integrin-containing membrane microdomains. J. Biol. Chem. 278:31251–60
    [Google Scholar]
89. Murter B, Pan X, Ophir E, Alteber Z, Azulay M et al. 2019. Mouse PVRIG has CD8⁺ T cell–specific coinhibitory functions and dampens antitumor immunity. Cancer Immunol. Res. 7:244–56
    [Google Scholar]
90. Nagumo Y, Iguchi-Manaka A, Yamashita-Kanemaru Y, Abe F, Bernhardt G et al. 2014. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice. PLOS ONE 9:e112415
    [Google Scholar]
91. Nakai R, Maniwa Y, Tanaka Y, Nishio W, Yoshimura M et al. 2010. Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci 101:1326–30
    [Google Scholar]
92. Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I et al. 2015. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J. Exp. Clin. Cancer Res. 34:30
    [Google Scholar]
93. Niu J, Nagrial A, Voskoboynik M, Chung HC, Lee DH et al. 2020. Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC. Ann. Oncol. 31:Suppl. 4S891–92 Abstr .)
    [Google Scholar]
94. Oda T, Ohka S, Nomoto A 2004. Ligand stimulation of CD155α inhibits cell adhesion and enhances cell migration in fibroblasts. Biochem. Biophys. Res. Commun. 319:1253–64
    [Google Scholar]
95. Okumura G, Iguchi-Manaka A, Murata R, Yamashita-Kanemaru Y, Shibuya A, Shibuya K 2020. Tumor-derived soluble CD155 inhibits DNAM-1–mediated antitumor activity of natural killer cells. J. Exp. Med. 217:4e20191290
    [Google Scholar]
96. Pende D, Bottino C, Castriconi R, Cantoni C, Marcenaro S et al. 2005. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol. Immunol. 42:463–69
    [Google Scholar]
97. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S et al. 2006. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 107:2030–36
    [Google Scholar]
98. Reymond N, Imbert AM, Devilard E, Fabre S, Chabannon C et al. 2004. DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J. Exp. Med. 199:1331–41
    [Google Scholar]
99. Rodriguez-Abreu D, Johnson ML, Hussein MA, Cobo M, Patel AJ et al. 2020. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J. Clin. Oncol. 38:159503 Abstr .)
    [Google Scholar]
100. Roman Aguilera A, Lutzky VP, Mittal D, Li XY, Stannard K et al. 2018. CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. OncoImmunology 7:e1424677
     [Google Scholar]
101. Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C et al. 2015. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. PNAS 112:6140–45
     [Google Scholar]
102. Samanta D, Ramagopal UA, Rubinstein R, Vigdorovich V, Nathenson SG, Almo SC 2012. Structure of Nectin-2 reveals determinants of homophilic and heterophilic interactions that control cell–cell adhesion. PNAS 109:14836–40
     [Google Scholar]
103. Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S et al. 2012. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol. Cell Biol. 90:109–15
     [Google Scholar]
104. Satoh-Horikawa K, Nakanishi H, Takahashi K, Miyahara M, Nishimura M et al. 2000. Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows homophilic and heterophilic cell-cell adhesion activities. J. Biol. Chem. 275:10291–99
     [Google Scholar]
105. Scott AC, Dundar F, Zumbo P, Chandran SS, Klebanoff CA et al. 2019. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571:270–74
     [Google Scholar]
106. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T et al. 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1:32–42
     [Google Scholar]
107. Seth S, Qiu Q, Danisch S, Maier MK, Braun A et al. 2011. Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells. J. Biol. Chem. 286:39153–63
     [Google Scholar]
108. Sharma A, Subudhi SK, Blando J, Scutti J, Vence L et al. 2019. Anti-CTLA-4 immunotherapy does not deplete FOXP3⁺ regulatory T cells (Tregs) in human cancers. Clin. Cancer Res. 25:1233–38
     [Google Scholar]
109. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K et al. 2013. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J. Exp. Med. 210:1695–710
     [Google Scholar]
110. Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C et al. 2004. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 4:73
     [Google Scholar]
111. Solecki DJ, Gromeier M, Mueller S, Bernhardt G, Wimmer E 2002. Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog. J. Biol. Chem. 277:25697–702
     [Google Scholar]
112. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR et al. 2009. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113:3503–11
     [Google Scholar]
113. Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O et al. 2009. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. PNAS 106:17858–63
     [Google Scholar]
114. Stengel KF, Harden-Bowles K, Yu X, Rouge L, Yin J et al. 2012. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clustering. PNAS 109:5399–404
     [Google Scholar]
115. Sullivan DP, Seidman MA, Muller WA 2013. Poliovirus receptor (CD155) regulates a step in transendothelial migration between PECAM and CD99. Am. J. Pathol. 182:1031–42
     [Google Scholar]
116. Sun H, Huang Q, Huang M, Wen H, Lin R et al. 2019. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology 70:168–83
     [Google Scholar]
117. Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S et al. 2004. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int. Immunol. 16:533–38
     [Google Scholar]
118. Takai Y, Miyoshi J, Ikeda W, Ogita H 2008. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat. Rev. Mol. Cell Biol. 9:603–15
     [Google Scholar]
119. Triki H, Charfi S, Bouzidi L, Ben Kridis W, Daoud J et al. 2019. CD155 expression in human breast cancer: clinical significance and relevance to natural killer cell infiltration. Life Sci 231:116543
     [Google Scholar]
120. Vallejo AN, Brandes JC, Weyand CM, Goronzy JJ 1999. Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence. J. Immunol. 162:6572–79
     [Google Scholar]
121. Vassena L, Giuliani E, Matusali G, Cohen EA, Doria M 2013. The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the ATR-mediated DNA damage response pathway. J. Gen. Virol. 94:2664–69
     [Google Scholar]
122. Waight JD, Chand D, Dietrich S, Gombos R, Horn T et al. 2018. Selective FcγR co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens. Cancer Cell 33:1033–47.e5
     [Google Scholar]
123. Wang B, Zhang W, Jankovic V, Golubov J, Poon P et al. 2018. Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8⁺ T cell dysfunction and maintain memory phenotype. Sci. Immunol. 3:eaat7061
     [Google Scholar]
124. Wang H, Qi J, Zhang S, Li Y, Tan S, Gao GF 2019. Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5. PNAS 116:988–96
     [Google Scholar]
125. Whelan S, Ophir E, Kotturi MF, Levy O, Ganguly S et al. 2019. PVRIG and PVRL2 are induced in cancer and inhibit CD8⁺ T-cell function. Cancer Immunol. Res. 7:257–68
     [Google Scholar]
126. Williams SMG, Laface D, Fayadat-Dilman L, Raghunathan G, Liang L, Seghezzi W 2020. Anti-TIGIT antibodies US Patent 10,618,518
127. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P et al. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67:235–42
     [Google Scholar]
128. Wu L, Mao L, Liu JF, Chen L, Yu GT et al. 2019. Blockade of TIGIT/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma. Cancer Immunol. Res. 7:1700–13
     [Google Scholar]
129. Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y 2017. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol. Immunother. 66:1367–75
     [Google Scholar]
130. Yamashita-Kanemaru Y, Takahashi Y, Wang Y, Tahara-Hanaoka S, Honda S et al. 2015. CD155 (PVR/Necl5) mediates a costimulatory signal in CD4⁺ T cells and regulates allergic inflammation. J. Immunol. 194:5644–53
     [Google Scholar]
131. Yong H, Cheng R, Li X, Gao G, Jiang X et al. 2019. CD155 expression and its prognostic value in postoperative patients with breast cancer. Biomed. Pharmacother. 115:108884
     [Google Scholar]
132. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E et al. 2009. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10:48–57
     [Google Scholar]
133. Yusa S, Catina TL, Campbell KS 2002. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J. Immunol. 168:5047–57
     [Google Scholar]
134. Zhang Q, Bi J, Zheng X, Chen Y, Wang H et al. 2018. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat. Immunol. 19:723–32
     [Google Scholar]
135. Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A 2015. DNAM-1 controls NK cell activation via an ITT-like motif. J. Exp. Med. 212:2165–82
     [Google Scholar]
136. Zhu Y, Paniccia A, Schulick AC, Chen W, Koenig MR et al. 2016. Identification of CD112R as a novel checkpoint for human T cells. J. Exp. Med. 213:167–76
     [Google Scholar]